MX2009013327A - Ingenieria basada en secuencias y optimizacion de anticuerpos de cadena simple. - Google Patents
Ingenieria basada en secuencias y optimizacion de anticuerpos de cadena simple.Info
- Publication number
- MX2009013327A MX2009013327A MX2009013327A MX2009013327A MX2009013327A MX 2009013327 A MX2009013327 A MX 2009013327A MX 2009013327 A MX2009013327 A MX 2009013327A MX 2009013327 A MX2009013327 A MX 2009013327A MX 2009013327 A MX2009013327 A MX 2009013327A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- single chain
- sequence based
- solubility
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
Abstract
La invención proporciona los métodos para utilizar el análisis basado en secuencia y las estrategias racionales para modificar y mejorar las propiedades estructurales y biofísicas de los anticuerpos de cadena simple (scFvs), incluyendo la estabilidad, la solubilidad, y la afinidad de enlace al antígeno. Estos métodos y las estrategias pueden ser utilizados individualmente o en combinación. Los métodos de la presente invención también incluyen el uso de una base de datos que comprende las secuencias de scFvs provenientes de una biblioteca de scFv experimentalmente seleccionada, de anticuerpos que han sido seleccionados por tener solubilidad y estabilidad superiores. La invención también proporciona los métodos para utilizar las propiedades encontradas para estos anticuerpos seleccionados, en un procedimiento general para reconformar los anticuerpos de scFv para mejorar las propiedades de estabilidad y de solubilidad de un fragmento de anticuerpo de cadena simple.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93711207P | 2007-06-25 | 2007-06-25 | |
US6905708P | 2008-03-12 | 2008-03-12 | |
PCT/CH2008/000284 WO2009000098A2 (en) | 2007-06-25 | 2008-06-25 | Sequence based engineering and optimization of single chain antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009013327A true MX2009013327A (es) | 2010-06-02 |
Family
ID=39855147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009013327A MX2009013327A (es) | 2007-06-25 | 2008-06-25 | Ingenieria basada en secuencias y optimizacion de anticuerpos de cadena simple. |
Country Status (20)
Country | Link |
---|---|
US (1) | US9908945B2 (es) |
EP (1) | EP2164961B1 (es) |
JP (2) | JP5506670B2 (es) |
KR (1) | KR101530723B1 (es) |
CN (1) | CN101688200B (es) |
AU (1) | AU2008267733B2 (es) |
BR (1) | BRPI0813287A2 (es) |
CA (1) | CA2689064C (es) |
DK (1) | DK2164961T3 (es) |
ES (1) | ES2532725T3 (es) |
HK (1) | HK1137035A1 (es) |
IL (1) | IL202352A (es) |
MX (1) | MX2009013327A (es) |
NZ (1) | NZ581470A (es) |
PL (1) | PL2164961T3 (es) |
PT (1) | PT2164961E (es) |
RU (1) | RU2010102064A (es) |
SI (1) | SI2164961T1 (es) |
WO (1) | WO2009000098A2 (es) |
ZA (1) | ZA200908314B (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ563580A (en) * | 2005-06-07 | 2010-09-30 | Esbatech An Alcon Biomedical R | Stable and soluble antibodies inhibiting TNFaplha |
ES2568436T3 (es) | 2006-03-31 | 2016-04-29 | Chugai Seiyaku Kabushiki Kaisha | Procedimiento para controlar la farmacocinética en sangre de anticuerpos |
CA2680564C (en) * | 2007-03-12 | 2018-05-01 | Esbatech Ag | Sequence based engineering and optimization of single chain antibodies |
DK2164961T3 (en) | 2007-06-25 | 2015-03-02 | Esbatech Alcon Biomed Res Unit | Sequence based forward position and optimization of single chain antibodies |
WO2009000099A2 (en) | 2007-06-25 | 2008-12-31 | Esbatech Ag | Methods of modifying antibodies, and modified antibodies with improved functional properties |
EP3689912A1 (en) | 2007-09-26 | 2020-08-05 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
EP4238993A3 (en) | 2008-04-11 | 2023-11-29 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
DK3241843T3 (da) | 2008-06-25 | 2021-09-06 | Novartis Ag | Opløselighedsoptimering af immunbindere |
KR20190133077A (ko) | 2008-06-25 | 2019-11-29 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | TNFα를 저해하는 안정한 가용성 항체 |
KR101882352B1 (ko) | 2008-06-25 | 2018-07-26 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화 |
CA3020290A1 (en) | 2008-06-25 | 2009-12-30 | Esbatech, An Alcon Biomedical Research Unit Llc | Stable and soluble antibodies inhibiting vegf |
EP2304033B1 (en) | 2008-06-30 | 2016-09-07 | ESBATech, an Alcon Biomedical Research Unit LLC | Functionalized polypeptides |
CN102088958A (zh) | 2008-07-10 | 2011-06-08 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 用于大分子的增强的递送的方法和组合物 |
US8399625B1 (en) | 2009-06-25 | 2013-03-19 | ESBATech, an Alcon Biomedical Research Unit, LLC | Acceptor framework for CDR grafting |
MX2012006626A (es) | 2009-12-22 | 2012-06-25 | Hoffmann La Roche | Agregacion dependiente de secuencia. |
KR101721187B1 (ko) * | 2009-12-23 | 2017-03-29 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 면역원성의 감소 방법 |
MX360336B (es) * | 2010-07-16 | 2018-10-30 | Adimab Llc Star | Colecciones de anticuerpos. |
JP5704386B2 (ja) * | 2010-10-12 | 2015-04-22 | 日本電気株式会社 | タンパク質分子のアミノ酸置換部位選択装置、置換アミノ酸選択装置、アミノ酸置換部位選択方法、置換アミノ酸選択方法、プログラムおよび記録媒体 |
UY33679A (es) * | 2010-10-22 | 2012-03-30 | Esbatech | Anticuerpos estables y solubles |
SG190727A1 (en) | 2010-11-30 | 2013-07-31 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
EP2476754A1 (en) * | 2011-01-14 | 2012-07-18 | Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts | Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scFv) |
KR101287625B1 (ko) * | 2011-10-10 | 2013-07-23 | 대유라디에터공업 주식회사 | 열교환기용 튜브 제조방법 |
JP6774164B2 (ja) | 2012-08-24 | 2020-10-21 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
TWI697501B (zh) | 2012-08-24 | 2020-07-01 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
WO2014163101A1 (ja) | 2013-04-02 | 2014-10-09 | 中外製薬株式会社 | Fc領域改変体 |
TWI808330B (zh) | 2014-12-19 | 2023-07-11 | 日商中外製藥股份有限公司 | 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法 |
TW202248212A (zh) | 2015-02-05 | 2022-12-16 | 日商中外製藥股份有限公司 | 包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途 |
GB201502590D0 (en) * | 2015-02-16 | 2015-04-01 | Lonza Ag | Method and apparatus for designing proteins |
WO2016199898A1 (ja) * | 2015-06-10 | 2016-12-15 | 公立大学法人 富山県立大学 | 活性型変異酵素の製造方法および新規活性型変異酵素、並びに可溶性化変異タンパク質の製造方法 |
EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE |
EP3494991A4 (en) | 2016-08-05 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATING TO IL-8 |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
TWI827585B (zh) | 2018-03-15 | 2024-01-01 | 日商中外製藥股份有限公司 | 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法 |
WO2022171771A1 (en) | 2021-02-12 | 2022-08-18 | Boehringer Ingelheim International Gmbh | Complement c3 antigen binding proteins |
US20220340894A1 (en) | 2021-03-09 | 2022-10-27 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same |
CA3210289A1 (en) | 2021-03-09 | 2022-09-15 | Anna Maria SOBIERAJ | Mage-a4 peptide-mhc antigen binding proteins |
WO2023110918A1 (en) | 2021-12-14 | 2023-06-22 | Cdr-Life Ag | Dual mhc-targeting t cell engager |
WO2023220038A1 (en) * | 2022-05-10 | 2023-11-16 | Amgen Inc. | Machine learning techniques for predicting thermostability |
US20240091262A1 (en) | 2022-09-14 | 2024-03-21 | Cdr-Life Ag | Mage-a4 peptide dual t cell engagers |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
EP0752248B1 (en) | 1992-11-13 | 2000-09-27 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
US6740734B1 (en) | 1994-01-14 | 2004-05-25 | Biovitrum Ab | Bacterial receptor structures |
SI9720020B (en) | 1996-02-09 | 2001-12-31 | Basf Ag | Human antibodies that bind human TNF alpha |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
EP0985039B1 (en) | 1997-06-12 | 2008-02-20 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
MY136203A (en) | 1998-08-11 | 2008-08-29 | Idec Pharma Corp | Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
WO2000035510A1 (en) | 1998-12-14 | 2000-06-22 | Osteotech, Inc. | Bone graft and guided bone regeneration method |
US6602977B1 (en) | 1999-04-19 | 2003-08-05 | Biovitrum Ab | Receptor structures |
SE9901379D0 (sv) | 1999-04-19 | 1999-04-19 | Pharmacia & Upjohn Ab | Receptor structures |
EP1479694B1 (en) | 1999-12-28 | 2016-10-26 | ESBATech, an Alcon Biomedical Research Unit LLC | Intrabodies ScFv with defined framework that is stable in a reducing environment |
BR0015875A (pt) | 2000-05-10 | 2003-06-24 | Mayo Foundation | Anticorpos igm humano com a capacidade de induzir remielinização, e usos diagnósticos e terapêutico dos mesmos, particularmente no sistema nervoso central |
ATE448301T1 (de) | 2000-09-08 | 2009-11-15 | Univ Zuerich | Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten |
US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
WO2002088171A2 (en) | 2001-04-26 | 2002-11-07 | Avidia Research Institute | Combinatorial libraries of monomer domains |
CA2453662A1 (en) * | 2001-07-19 | 2003-01-30 | Stefan Ewert | Modification of human variable domains |
HUE048922T2 (hu) | 2002-05-22 | 2020-09-28 | Novartis Ag | Immunglobulin vázrégiók, amelyek intracelluláris környezetben fokozott stabilitást mutatnak, továbbá eljárások azonosításukra |
CA2531482A1 (en) | 2003-06-30 | 2005-01-20 | Centocor, Inc. | Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses |
AU2003264100A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of a bilin-binding protein with affinity for a given target |
RU2006122946A (ru) | 2003-11-28 | 2008-01-10 | Астразенека Аб (Se) | Антитела |
WO2006083275A2 (en) | 2004-05-21 | 2006-08-10 | The Uab Research Foundation | Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof |
GB0416651D0 (en) | 2004-07-26 | 2004-08-25 | Proteo Target Aps | Polypeptide |
US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
NZ563580A (en) | 2005-06-07 | 2010-09-30 | Esbatech An Alcon Biomedical R | Stable and soluble antibodies inhibiting TNFaplha |
PL2481753T3 (pl) | 2005-12-13 | 2018-09-28 | Eli Lilly And Company | Przeciwciała anty-IL-17 |
AU2007272224B2 (en) | 2006-07-10 | 2013-05-02 | Novartis Ag | scFv antibodies which pass epithelial and/or endothelial layers |
CA2680564C (en) | 2007-03-12 | 2018-05-01 | Esbatech Ag | Sequence based engineering and optimization of single chain antibodies |
DK2164961T3 (en) | 2007-06-25 | 2015-03-02 | Esbatech Alcon Biomed Res Unit | Sequence based forward position and optimization of single chain antibodies |
WO2009000099A2 (en) | 2007-06-25 | 2008-12-31 | Esbatech Ag | Methods of modifying antibodies, and modified antibodies with improved functional properties |
-
2008
- 2008-06-25 DK DK08757277.2T patent/DK2164961T3/en active
- 2008-06-25 BR BRPI0813287-9A2A patent/BRPI0813287A2/pt not_active Application Discontinuation
- 2008-06-25 NZ NZ581470A patent/NZ581470A/xx not_active IP Right Cessation
- 2008-06-25 SI SI200831414T patent/SI2164961T1/sl unknown
- 2008-06-25 EP EP08757277.2A patent/EP2164961B1/en active Active
- 2008-06-25 AU AU2008267733A patent/AU2008267733B2/en not_active Ceased
- 2008-06-25 PL PL08757277T patent/PL2164961T3/pl unknown
- 2008-06-25 PT PT87572772T patent/PT2164961E/pt unknown
- 2008-06-25 JP JP2010513600A patent/JP5506670B2/ja active Active
- 2008-06-25 US US12/145,749 patent/US9908945B2/en active Active
- 2008-06-25 RU RU2010102064/10A patent/RU2010102064A/ru unknown
- 2008-06-25 WO PCT/CH2008/000284 patent/WO2009000098A2/en active Application Filing
- 2008-06-25 KR KR1020097027050A patent/KR101530723B1/ko active IP Right Grant
- 2008-06-25 CN CN200880021937XA patent/CN101688200B/zh active Active
- 2008-06-25 CA CA2689064A patent/CA2689064C/en not_active Expired - Fee Related
- 2008-06-25 ES ES08757277.2T patent/ES2532725T3/es active Active
- 2008-06-25 MX MX2009013327A patent/MX2009013327A/es active IP Right Grant
-
2009
- 2009-11-24 ZA ZA2009/08314A patent/ZA200908314B/en unknown
- 2009-11-26 IL IL202352A patent/IL202352A/en active IP Right Grant
-
2010
- 2010-04-09 HK HK10103507.8A patent/HK1137035A1/xx not_active IP Right Cessation
-
2013
- 2013-10-17 JP JP2013216065A patent/JP2014051508A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2008267733A1 (en) | 2008-12-31 |
BRPI0813287A2 (pt) | 2014-12-30 |
NZ581470A (en) | 2013-04-26 |
DK2164961T3 (en) | 2015-03-02 |
WO2009000098A2 (en) | 2008-12-31 |
JP2014051508A (ja) | 2014-03-20 |
ES2532725T3 (es) | 2015-03-31 |
CN101688200A (zh) | 2010-03-31 |
PL2164961T3 (pl) | 2015-08-31 |
EP2164961B1 (en) | 2015-01-07 |
JP5506670B2 (ja) | 2014-05-28 |
KR101530723B1 (ko) | 2015-06-22 |
US9908945B2 (en) | 2018-03-06 |
KR20100028053A (ko) | 2010-03-11 |
EP2164961A2 (en) | 2010-03-24 |
CA2689064C (en) | 2018-04-24 |
SI2164961T1 (sl) | 2015-05-29 |
CA2689064A1 (en) | 2008-12-31 |
RU2010102064A (ru) | 2011-07-27 |
JP2010532324A (ja) | 2010-10-07 |
HK1137035A1 (en) | 2010-07-16 |
AU2008267733B2 (en) | 2013-11-14 |
IL202352A0 (en) | 2011-08-01 |
US20090028848A1 (en) | 2009-01-29 |
ZA200908314B (en) | 2011-02-23 |
IL202352A (en) | 2015-06-30 |
PT2164961E (pt) | 2015-04-08 |
CN101688200B (zh) | 2012-08-08 |
WO2009000098A3 (en) | 2009-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009013327A (es) | Ingenieria basada en secuencias y optimizacion de anticuerpos de cadena simple. | |
IN2009DN05758A (es) | ||
MX2009013328A (es) | Metodos para modificar anticuerpos, y anticuerpos modificados con propiedades funcionales mejoradas. | |
AR095980A1 (es) | Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización | |
AR083747A1 (es) | Anticuerpos anti-il-23 | |
ATE431423T1 (de) | Verfahren zum screening der leichten kette eines antikörpers | |
MX346024B (es) | Optimización de solubilidad de inmuno-aglutinantes. | |
NZ706377A (en) | Il-6 antagonists and uses thereof | |
UA99701C2 (ru) | Человеческое моноклональное антитело, которое специфически связывается с лигандом-1 запрограммированной гибели клеток (pd-l1) | |
PH12015501505A1 (en) | Antibodies that bind to tl1a and their uses | |
GEP20125517B (en) | Humanized monoclonical antibodies to hepatocyte growth factor | |
CR20110577A (es) | Proteínas de unión a il-1 | |
MXPA06010715A (es) | Anticuerpo del receptor del factor de crecimiento humano anti-epidermico. | |
GEP20094829B (en) | Fully human antibodies against human 4-1bb (cd137) | |
NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
TN2014000120A1 (en) | Cd27l antigen binding proteins | |
UA106070C2 (uk) | Антитіло, що специфічно зв'язується з egfr і her3 | |
NO20092285L (no) | Humane, monoklonale antistoffer til BTLA og fremgangsmater for anvendelse | |
DE602006013029D1 (de) | Anti-egfr-antikörper | |
IN2014MN00873A (es) | ||
MX342413B (es) | Anticuerpos para metaloproteinasa-9 de matriz. | |
MX2018007630A (es) | Anticuerpos contra la metaloproteinasa de matriz 9. | |
NZ720765A (en) | Antibodies and methods of use | |
DE602005027399D1 (de) | Für humane matriptase spezifische bindungsproteine | |
MX2010006767A (es) | Anticuerpos de virus de hepatitis c. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |